Ahmad A. Alfadhli

Kuwait City, KU, Kuwait

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Impact of Tumor Necrosis Factor Antagonist Therapy on Circulating Angiopoietin-like Protein 8 (ANGPTL8) Levels in Crohn's Disease-A Prospective Multi-Center Study.

Impact of Tumor Necrosis Factor Antagonist Therapy on Circulating Angiopoietin-like Protein 8 (ANGPTL8) Levels in Crohn's Disease-A Prospective Multi-Center Study.

Journal: Journal of clinical medicine

Published: April 11, 2025

Artificial Intelligence for Adenoma and Polyp Detection During Screening and Surveillance Colonoscopy: A Randomized-Controlled Trial.

Artificial Intelligence for Adenoma and Polyp Detection During Screening and Surveillance Colonoscopy: A Randomized-Controlled Trial.

Journal: Journal of clinical medicine

Published: December 20, 2024

Predictive Factors of Significant Findings on Capsule Endoscopy in Patients with Suspected Small Bowel Bleeding.

Predictive Factors of Significant Findings on Capsule Endoscopy in Patients with Suspected Small Bowel Bleeding.

Journal: Diagnostics (Basel, Switzerland)

Published: August 30, 2024

Relationship between Ustekinumab trough concentrations and clinical, biochemical and endoscopic outcomes in Crohn's disease: A multi-center nationwide retrospective study (TARGET STUDY).

Relationship between Ustekinumab trough concentrations and clinical, biochemical and endoscopic outcomes in Crohn's disease: A multi-center nationwide retrospective study (TARGET STUDY).

Journal: Medicine

Published: July 05, 2024

Immunogenicity of Hepatitis B Vaccination in Patients with Ulcerative Colitis on Infliximab Is Attenuated Compared to Those on 5-Aminosalicylic Acid Therapies: A Prospective Observational Study.

Immunogenicity of Hepatitis B Vaccination in Patients with Ulcerative Colitis on Infliximab Is Attenuated Compared to Those on 5-Aminosalicylic Acid Therapies: A Prospective Observational Study.

Journal: Vaccines

Published: February 28, 2024

Effectiveness of biologic therapies in achieving treatment targets in inflammatory bowel disease; real-world data from the Middle East (ENROLL study).

Effectiveness of biologic therapies in achieving treatment targets in inflammatory bowel disease; real-world data from the Middle East (ENROLL study).

Journal: Frontiers in pharmacology

Published: February 19, 2024

Relationship Between Patient Demographics and Biologic Therapy Use in Inflammatory Bowel Disease. A Single Center Cross-Sectional Study.

Relationship Between Patient Demographics and Biologic Therapy Use in Inflammatory Bowel Disease. A Single Center Cross-Sectional Study.

Journal: JGH open : an open access journal of gastroenterology and hepatology

Published: October 07, 2023

Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study).

Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study).

Journal: Frontiers in pharmacology

Published: June 20, 2023

Impact of tumor necrosis factor antagonist combination and anti-integrin therapies on body mass index in inflammatory bowel disease: A cross-sectional study.

Impact of tumor necrosis factor antagonist combination and anti-integrin therapies on body mass index in inflammatory bowel disease: A cross-sectional study.

Journal: Frontiers in medicine

Published: September 15, 2022

COVID-19 Vaccine Booster Dose Willingness among Patients with Inflammatory Bowel Disease on Infliximab and Vedolizumab: A Cross-Sectional Study.

COVID-19 Vaccine Booster Dose Willingness among Patients with Inflammatory Bowel Disease on Infliximab and Vedolizumab: A Cross-Sectional Study.

Journal: Vaccines

Published: June 09, 2022

Immunogenicity of BNT162b2 Vaccine Booster Dose in Patients With Inflammatory Bowel Disease Receiving Infliximab Combination Therapy: A Prospective Observational Study.

Immunogenicity of BNT162b2 Vaccine Booster Dose in Patients With Inflammatory Bowel Disease Receiving Infliximab Combination Therapy: A Prospective Observational Study.

Journal: Frontiers in medicine

Published: May 01, 2022

Impact of BNT162b2 mRNA Vaccination on the Development of Short and Long-Term Vaccine-Related Adverse Events in Inflammatory Bowel Disease: A Multi-Center Prospective Study.

Impact of BNT162b2 mRNA Vaccination on the Development of Short and Long-Term Vaccine-Related Adverse Events in Inflammatory Bowel Disease: A Multi-Center Prospective Study.

Journal: Frontiers in medicine

Published: February 22, 2022

Showing 1-12 of 23

Last Updated: 09/26/2026